Pharmacy & Therapeutics - April 2008 - (Page 247) EDITORIAL continued from page 193 MEDICATION ERRORS continued from page 194 DRUG FORECAST continued from page 219 for treatment-resistant major depression. J Clin Psychiatry 2001;62(Suppl 18):12–17. 45. Szuba MP, Hornig-Rohan M, Amsterdam JD. Rapid conversion from one monoamine oxidase inhibitor to another. J Clin Psychiatry 1997;58(7):307–310. 46. Jounela AJ, Kivimaki T. Possible sensitivity to meperidine in phenylketonuria. N Engl J Med 1973;288(26):1411. 47. Mitchell RS. Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Ann Intern Med 1955;42(2):417–424. 48. Papp C, Benaim S. Toxic effects of iproniazid in a patient with angina. Br Med J 1958(5103):1070–1072. 49. Shee JC. Dangerous potentiation of pethidine by iproniazid, and its treatment. Br Med J 1960;5197:507–509. 50. Vigran IM. Dangerous potentiation of meperidine hydrochloride by pargyline hydrochloride. JAMA 1964;187:953–954. 51. Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. Lancet 1991; 337(8735):246. 52. Spencer GT, Smith SE. Dangers of monoamine oxidase inhibitors. Br Med J 1963; 5332:750. 53. Codd EE, Shank RP, Schupsky JJ, et al. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: Structural determinants and role in antinociception. J Pharmacol Exp Ther 1995;274(3):1263–1270. 54. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 2005;95(4):434–441. 55. Browne B, Linter S. Monoamine oxidase inhibitors and narcotic analgesics: A critical review of the implications for treatment. Br J Psychiatry 1987;151:210–212. 56. Papakostas GI, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006; 60(12):1350–1355. 57. Shulman KI, Walker SE. A reevaluation of dietary restrictions for irreversible monoamine oxidase inhibitors. Psychiatr Ann 2001;31:378–384. I a long-term family business, and we can disregard the notion that we will never have a transaction-based model. However, we can heartily embrace the idea of value—not power—driving health care and that the two key outcomes of quality of life and longevity should indeed be high on our priority list for the future. If Professor Nordhaus is right—that 50% of our productivity is the result of improvements in health and in health care—then by all means let’s invest more in the health care system, not less. Let’s embrace the idea of the value of the doctor–patient relationship, and let’s give providers contracts in which they will be paid more for better outcomes instead of being paid for encounters or procedures. I recommend that all P&T committee members read Dr. Beauchamp’s short book. It is definitely wor th devoting some time to a discussion of its main points. We would all be ser ving our patients better by airing the topics that the courageous author has brought to the fore. As always, I am interested in your views. You can reach me at my e-mail address, david.nash@jefferson.edu, and you can also visit my new blog at http:// departmentofhealthpolicy.blogspot.com. 7. Patients also need information. Before a narcotic is administered, the staff member should repeat the name of the medication out loud to the patient as another way of confirming the drug name. 8. Patients should be carefully monitored. Facilities should implement policies specifying the scope, frequency, and duration of monitoring that should take place before discharging patients who have just received a parenteral narcotic agent. REFERENCE 1. Pennsylvania Patient Reporting System. Patient Safety Advisory, Vol 4, No. 3, September 2007. Available at: www. psa.state.pa.us/psa/lib/psa/advisories/ v4n3_september 2007/sept_2007_v4_n3_ article_medication_pairs.pdf. Accessed March 5, 2008. The reports described in this column were received through the USP–ISMP Medication Errors Reporting Program (MERP). Errors, close calls, or hazardous con ditions may be repor ted on the ISMP (www.ismp.org) or the USP (www.usp. org) Web site or communicated directly to ISMP by calling 1-800-FAILSAFE or via e-mail at ismpinfo@ismp.org. I REFERENCE 1. Beauchamp G. Slaves to Medicine: How to Ransom Your Health Care from Power & Money. Brown Books, Dallas, TX: 2007. I COMING SOON TO P&T EDITORIAL: Open Public Hearing No. 4 David B. Nash, MD, MBA DRUG FORECAST: Omega-3-Acid Ethyl Esters (Lovaza, formerly Omacor) for Severe Hyper triglyceridemia Renee R. Koski, PharmD, CACP FEATURE ARTICLES: Drug Utilization Evaluation: Prescribing Trends with Daptomycin (Cubicin) for the Treatment of Gram-Positive Infections Noreen H. Chan Tompkins, PharmD, and Stephen J. Harnicar, PharmD Drug Therapy: Persistence and Risk Of Reinfarction Fadia T. Shaya, PhD, MPH; Anna Gu, MA; and Xia Yan, MS Vol. 33 No. 4 • April 2008 • P&T® 247 http://www.psa.state.pa.us/psa/lib/psa/advisories/v4n3_september2007/sept_2007_v4_n3_article_medication_pairs.pdf http://www.psa.state.pa.us/psa/lib/psa/advisories/v4n3_september2007/sept_2007_v4_n3_article_medication_pairs.pdf http://www.psa.state.pa.us/psa/lib/psa/advisories/v4n3_september2007/sept_2007_v4_n3_article_medication_pairs.pdf http://www.psa.state.pa.us/psa/lib/psa/advisories/v4n3_september2007/sept_2007_v4_n3_article_medication_pairs.pdf http://www.ismp.org http://www.usp.org http://www.usp.org http://departmentofhealthpolicy.blogspot.com http://departmentofhealthpolicy.blogspot.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.